CDX2 and prostate carcinoma: Prostatic adenocarcinomas with intestinal differentiation had a higher rate of positivity; except for one research work, where a lymph node metastasis and a brain metastasis both exhibited weak (1+) positivity for CDX2, metastatic deposits of prostate cancer have all tested negative for this marker [30].